Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Gross Margin (2021 - 2025)

Historic Gross Margin for Evoke Pharma (EVOK) over the last 5 years, with Q3 2025 value amounting to 97.62%.

  • Evoke Pharma's Gross Margin rose 15400.0% to 97.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 97.02%, marking a year-over-year increase of 4700.0%. This contributed to the annual value of 96.52% for FY2024, which is 4200.0% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Gross Margin is 97.62%, which was up 15400.0% from 95.53% recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Gross Margin ranged from a high of 98.65% in Q1 2025 and a low of 28.39% during Q1 2021
  • For the 5-year period, Evoke Pharma's Gross Margin averaged around 87.41%, with its median value being 94.67% (2024).
  • The largest annual percentage gain for Evoke Pharma's Gross Margin in the last 5 years was 661700bps (2022), contrasted with its biggest fall of -45100bps (2022).
  • Over the past 5 years, Evoke Pharma's Gross Margin (Quarter) stood at 62.09% in 2021, then grew by 23bps to 76.13% in 2022, then grew by 27bps to 96.48% in 2023, then fell by 0bps to 96.42% in 2024, then increased by 1bps to 97.62% in 2025.
  • Its last three reported values are 97.62% in Q3 2025, 95.53% for Q2 2025, and 98.65% during Q1 2025.